Esperion to Participate in Upcoming BTIG Biotech Conference
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion is a company dedicated to discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases.
The company focuses on improving outcomes for patients with high cholesterol by breaking through barriers that prevent patients from reaching their goals. Esperion's approach aligns with healthcare providers' trend towards reducing LDL-cholesterol levels as low as possible, as soon as possible.
For more information about Esperion and its work, interested parties can visit esperion.com and esperionscience.com, or follow the company on X (formerly Twitter) at twitter.com/EsperionInc.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione alla prossima Conferenza BTIG Biotech che si terrà lunedì 5 agosto 2024, alle 16:00 ET. Esperion è un'azienda dedicata alla scoperta, sviluppo e commercializzazione di medicinali innovativi per pazienti con o a rischio di malattie cardiovascolari e cardiometaboliche.
L'azienda si concentra su migliorare i risultati per i pazienti con colesterolo alto, superando le barriere che ostacolano i pazienti nel raggiungere i loro obiettivi. L'approccio di Esperion è in linea con la tendenza dei fornitori di assistenza sanitaria a ridurre i livelli di colesterolo LDL il più possibile e il prima possibile.
Per maggiori informazioni su Esperion e il suo operato, le parti interessate possono visitare esperion.com e esperionscience.com, o seguire l'azienda su X (ex Twitter) all'indirizzo twitter.com/EsperionInc.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la próxima Conferencia BTIG Biotech que se llevará a cabo el lunes 5 de agosto de 2024, a las 4 p.m. ET. Esperion es una empresa dedicada a descubrir, desarrollar y comercializar medicamentos innovadores para pacientes con o en riesgo de enfermedades cardiovasculares y cardiometabólicas.
La empresa se centra en mejorar los resultados para los pacientes con colesterol alto superando barreras que impiden que los pacientes alcancen sus objetivos. El enfoque de Esperion se alinea con la tendencia de los proveedores de atención médica de reducir los niveles de colesterol LDL lo más bajo posible y lo más pronto posible.
Para obtener más información sobre Esperion y su trabajo, las partes interesadas pueden visitar esperion.com y esperionscience.com, o seguir a la empresa en X (anteriormente Twitter) en twitter.com/EsperionInc.
Esperion (NASDAQ: ESPR)은 2024년 8월 5일 월요일 오후 4시 ET에 열리는 BTIG 생명공학 컨퍼런스에 참여할 것이라고 발표했습니다. Esperion은 심혈관 및 심혈관 대사 질환이 있는 환자 또는 위험에 처한 환자를 위해 혁신적인 약물을 발견, 개발 및 상용화하는 데 전념하는 회사입니다.
이 회사는 고콜레스테롤 환자의 결과 개선에 중점을 두고 환자가 목표를 달성하지 못하도록 하는 장벽을 허물고 있습니다. Esperion의 접근 방식은 가능한 한 빨리 LDL-콜레스테롤 수치를 가능한 낮추려는 의료 제공자의 경향과 일치합니다.
Esperion과 그 작업에 대한 자세한 정보는 관심 있는 사람들이 esperion.com 및 esperionscience.com를 방문하거나 X(구 Twitter)에서 회사의 twitter.com/EsperionInc를 팔로우할 수 있습니다.
Esperion (NASDAQ: ESPR) a annoncé sa participation à la prochaine Conférence BTIG Biotech qui se déroulera le lundi 5 août 2024 à 16h00 ET. Esperion est une entreprise dédiée à la découverte, au développement et à la commercialisation de médicaments innovants pour les patients atteints de maladies cardiovasculaires et cardiométaboliques ou à risque.
L'entreprise se concentre sur l'amélioration des résultats pour les patients présentant un taux de cholestérol élevé en surmontant les obstacles qui empêchent les patients d'atteindre leurs objectifs. L'approche d'Esperion s'aligne sur la tendance des prestataires de soins de santé à réduire les niveaux de cholestérol LDL le plus bas possible et le plus tôt possible.
Pour plus d'informations sur Esperion et son travail, les parties intéressées peuvent visiter esperion.com et esperionscience.com, ou suivre l'entreprise sur X (anciennement Twitter) à l'adresse twitter.com/EsperionInc.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der bevorstehenden BTIG Biotech-Konferenz am Montag, den 5. August 2024, um 16:00 Uhr ET bekannt gegeben. Esperion ist ein Unternehmen, das sich der Entdeckung, Entwicklung und Vermarktung innovativer Medikamente für Patienten mit oder mit Risiko für Herz-Kreislauf- und kardiometabolische Erkrankungen widmet.
Das Unternehmen konzentriert sich darauf, die Ergebnisse für Patienten mit hohem Cholesterinspiegel zu verbessern, indem es Barrieren überwindet, die Patienten daran hindern, ihre Ziele zu erreichen. Esperions Ansatz entspricht dem Trend der Gesundheitsdienstleister, die LDL-Cholesterinwerte so niedrig wie möglich und so schnell wie möglich zu senken.
Für weitere Informationen über Esperion und seine Arbeit können Interessierte esperion.com und esperionscience.com besuchen oder das Unternehmen auf X (ehemals Twitter) unter twitter.com/EsperionInc folgen.
- None.
- None.
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) participating in the BTIG Biotech Conference?
What is the main focus of Esperion's (ESPR) work?
How does Esperion (ESPR) align with current healthcare trends?
Where can investors find more information about Esperion (ESPR)?
